Dr. Megan Kruse, Dr. William Gradishar, & Dr. Ajaz Khan - Integrating T-DXd Across HER2+ Care

Community Health Media · Jun 25, 2026 · 40m

How should clinicians integrate T-DXd across the entire HER2-positive breast cancer treatment continuum?

Dr. Megan Kruse, Dr. William Gradishar, and Dr. Ajaz Khan discuss the evolving role of trastuzumab deruxtecan (T-DXd) in early-stage and metastatic HER2-positive breast cancer. From DESTINY-Breast11 and DESTINY-Breast05 to first-line metastatic DESTINY-Breast09 strategies, the conversation explores how recent data are reshaping treatment decisions, patient selection, toxicity management, and long-term sequencing approaches.

Topics discussed include:

DESTINY-Breast11 and neoadjuvant T-DXd…